NorthStar to Suspend Production of Mo-99 Radioisotopes

NorthStar Medical Radioisotopes, will suspend manufacturing and commercialization of molybdenum-99 (Mo-99) by the end of 2023.

NorthStar Therapeutics will continue and augment its ongoing work to produce and commercialize two critical radiotherapeutics that are currently in short supply — Actinium-225 (Ac-225) and Copper-67 (Cu-67). These are the radioisotopes essential for a large number of radiopharmaceutical products being investigated and are used to treat various forms of cancer. NorthStar will also continue the build-out and expansion of its radiopharmaceutical development services, including a Contract Development and Manufacturing Operations group, focused on supporting the development and production of radiopharmaceuticals.

To read more please visit:     

NorthStar to Suspend Production of Mo-99 Radioisotopes

Source: Beloit Daily News